LYMPHATIC TRANSPORT OF LIPOSOME-ENCAPSULATED AGENTS - EFFECTS OF LIPOSOME SIZE FOLLOWING INTRAPERITONEAL ADMINISTRATION
LYMPHATIC TRANSPORT OF LIPOSOME-ENCAPSULATED AGENTS - EFFECTS OF LIPOSOME SIZE FOLLOWING INTRAPERITONEAL ADMINISTRATION
复制标题
DOI:
10.1002/jps.2600740902
复制
发表时间:
1985-01-01
影响因子:
3.8
通讯作者:
HUNT, CA
中科院分区:
文献类型:
--
作者:
HIRANO, K;HUNT, CA
Liposomal encapsulation can limit passage of a drug from a peritoneal administration site to blood, while enhancing lymphatic transport. We evaluated the effects of liposome size on lymphatic transport after intraperitoneal administration. Liposomes tested had mean diameters of either 0.72, 0.46, 0.17, or 0.048 .mu.m and identical compositions. [14C]Sucrose was the aqueous space marker (model drug), Doses were given to thoracic-duct-cannulated rats. The subsequent 0-5 h time-course of carbon-14 was quantified in thoracic lymph, several lymph nodes, blood, and urine. Calibration studies indicated a maximum of .apprx. 30% of the absorbed dose could be collected in thoracic lymph. Carbon-14 levels in the various nodes covered a 1000-fold range, and relatively high levels were observed in the left mediastinal, parathymic, cisternal, and renal lymph nodes. Liposome stability in vivo and in vitro increased with decreasing size. Absorption from the peritoneal cavity was independent of size. The smallest liposomes was collected in lymph with little lymph node retention. The largest liposomes were retained most by lymph nodes, and would be the best prototypical carrier of the group if increased therapeutic availability within both lymph and lymph nodes is desired. The results implicate other, unexplored physical and physiological variables as potentially of equal importance.